Published in AIDS Weekly, January 23rd, 2006
The study will compare two doses of the MVA nef vaccine (5x10 E8 and 10E8) with Imvamune (10E8) in subjects with CD4 counts down to 250 cells/microliter. This group of patients has a more advanced state of the HIV disease than those patients studied in the company's earlier phase I/II study.
To-date, no serious or unexpected reactions were seen in these patients after vaccination with the MVA nef vaccine or Imvamune. In addition, initial data confirms that the vaccine is strongly immunogenic and thereby reinforces the promising results...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.